Some of you will have met our good friend, the inspirational Dr. Brian Koffman of CLL Society Inc. when he spoke at at our first Information Day last year. Brian has bravely shared that after 69 months on #ibrutinib his #CLL is relapsing and that he is joining a CAR-T #clinicaltrial. He plans to share his experiences and know many of you will want to follow his journey as he blogs. We send him all our love and best wishes. ow.ly/Meu030iAJ5N... See MoreSee Less
Combinations Continue to Push #CLL Field Forward With multiple combinations on the horizon, Barrientos said that subpopulations of patients who have not benefitted from current regimens will now have a greater opportunity to achieve response via OncLive.com ow.ly/WDC630iw2n7... See MoreSee Less
Study identifies protein JAK2 as main player in causing graft-versus-host disease (GVHD) a potential life-threatening side effect of stem cell transplants that happens when transplanted immune cells attack the patient’s healthy tissue via Lymphoma News Today ow.ly/MUSr30iw2LI... See MoreSee Less
After 2 failed rounds of Chemotherapy Bob Azopardi a #CLL patient joined an #Ibrutinib #clinicaltrial. He progressed well for the next 4 years but then developed resistance. His team switched him to a #Venetoclax trial; this is his story. Via Cornell University youtu.be/GsGeI3VuR-w... See MoreSee Less
Stem cell vaccine immunizes lab mice against multiple cancers via EurekAlert! "...injecting mice with... iPSCs launched a strong immune response against breast, lung & skin cancers... also prevented relapses in animals that had tumors removed" ow.ly/V9GQ30isrCN... See MoreSee Less
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses in animals that had tumors removed. The work appears in the journal Cell St...
In interview with Targeted Oncology Dr. O’Brien, discusses the tremendous impact that has been seen with #ibrutinib following the long-term follow-up of the RESONATE studies & highlights where this regimen is headed in the future of treatment for #CLL patients. ow.ly/2IBL30isrWh... See MoreSee Less
Susan O’Brien, MD, discusses the tremendous impact that has been seen with ibrutinib following the long-term follow-up of the RESONATE studies and highlights where this regimen is headed in the future of treatment for patients with CLL.
The impact of cancer-specific stress on psychological and physical functioning among patients with CLL was not previously well-understood. For this study, researchers evaluated whether cancer-specific stress at treatment initiation would predict for psychological and physical functioning.
Natural killer cells 'a hundred times cheaper' than CAR-T. Dr. Katy Rezvani's cellular therapy team at the MD Anderson Cancer Center have been able to manufacture c. 40 million CD19-targeting chimeric natural killer cells in 2 wks using cells drawn frm umbilical cord blood. ow.ly/AniH30iop2J... See MoreSee Less